News
James B. Bell
- August 13, 2023
Shares of Eli Lilly & Co. (LLY) skyrocketed by a staggering 9.0% in premarket trading on Tuesday, hitting an all-time high. The surge came as the pharmaceutical giant reported second-quarter earnings and revenue that exceeded expectations, and significantly raised its full-year outlook. This phenomenal performance was bolstered by the $579 million received from the sale of rights for Baqsimi.
Net income for the quarter climbed to $1.76 billion, or $1.95 per share, a significant jump from $952.5 million, or $1.05 per share, during the same period last year. Adjusted earnings per share, excluding one-time items, stood at $2.11, surpassing the FactSet consensus of $1.98 per share. Revenue also saw substantial growth, surging 28.1% to reach $8.31 billion, well above the FactSet consensus of $7.58 billion.
The remarkable increase in revenue was driven by a 29% jump in volume, fueled by the growth of Mounjaro, Verzenio, Jardiance, and Taltz. However, this increase was partially offset by a decline in volume from Alimta due to the loss of exclusivity.
Buoyed by this stellar performance, Eli Lilly & Co. has raised its guidance ranges for adjusted earnings per share for 2023 to $9.70 to $9.90 from $8.65 to $8.85, reflecting strong confidence in its future prospects. Additionally, the company has revised its revenue outlook for 2023 to $33.4 billion to $33.9 billion from $31.2 billion to $31.7 billion.
These robust figures paint a highly optimistic picture for Eli Lilly & Co., with the stock poised to open well above its previous record close of $468.98 on June 30. Year to date, the company's shares have rallied by an impressive 24.1%, outpacing the S&P 500's 17.7% growth over the same period.
Eli Lilly & Co.'s exceptional performance in the second quarter, coupled with the raised outlook for the year, cements its position as a frontrunner in the pharmaceutical industry. With a solid foundation and a promising future, the company continues to build on its success and deliver value to its shareholders.
Related Articles
Commercial and Industrial Loans: A Key Economic Driver
This article explores the decline in commercial and industrial loans and its potential implications for credit conditions and overall economic growth. It highli...
Changes to Araguaia Nickel Project
Horizonte Minerals announces changes to its Araguaia nickel project, leading to higher capital expenditure and a delayed production schedule.
Deutz Lifts Full-Year Profitability Guidance, Shares Climb
Shares of Deutz have seen a significant increase after the company raised its full-year profitability guidance, citing higher third-quarter revenue and earnings...